Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CGON
$58.34
$
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Beta
1.336
Average Volume
Market Cap
Last Dividend
CIK
0001991792
ISIN
US1569441009
CUSIP
156944100
CEO
Arthur Kuan
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
113
IPO Date
2024-01-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference | IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA. | GlobeNewsWire | 2026-02-23 08:00:00 |
| CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale | Connecticut-based Braidwell sold 1,412,746 shares of CG Oncology, with an estimated transaction value of $58.46 million (quarterly average prices). Meanwhile, the quarter-end stake value decreased by $54.59 million, reflecting both share sale and price moves. | The Motley Fool | 2026-02-19 16:55:50 |
| CG Oncology (NASDAQ:CGON) and Geron (NASDAQ:GERN) Head-To-Head Comparison | Geron (NASDAQ: GERN - Get Free Report) and CG Oncology (NASDAQ: CGON - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Analyst Ratings This is a summary of current recommendations | Defense World | 2026-02-10 01:46:45 |
| CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-15 15:15:57 |
| CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites. | Zacks Investment Research | 2026-01-15 11:31:03 |
| CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene | CG Oncology maintains a "Strong Buy" rating, driven by significant pipeline progress and multiple upcoming catalysts in 2026. Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Early enrollment completion in the phase 3 PIVOT-006 trial for IR-NMIBC accelerates topline data to 1H 2026, positioning the company for a potential first FDA approval in this segment. | Seeking Alpha | 2026-01-11 08:30:11 |
| CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule | GlobeNewsWire | 2026-01-09 08:30:00 |
| CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference | IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California. | GlobeNewsWire | 2026-01-06 08:00:00 |
| CG Oncology Undervalued Going Into A Busy 2026 | CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities. | Seeking Alpha | 2025-12-23 04:43:51 |
| CG Oncology (NASDAQ:CGON) Reaches New 1-Year High – What’s Next? | CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) shares reached a new 52-week high during trading on Friday. The company traded as high as $46.01 and last traded at $44.84, with a volume of 98696 shares changing hands. The stock had previously closed at $44.73. Analysts Set New Price Targets Several equities research analysts | Defense World | 2025-12-07 02:40:45 |
| New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer | IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which demonstrated promising efficacy, safety and tolerability. These data will be presented today as Late-Breaking Abstracts at the Society of Urologic Oncology (SUO) 26th Annual Meeting. | GlobeNewsWire | 2025-12-05 08:30:00 |
| CG Oncology Announces New Board Member and Board Transition | - Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. | GlobeNewsWire | 2025-11-26 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-01-13 | 2026-01-13 | View Filing |
| 424B5 | 2026-01-13 | 2026-01-13 | View Filing |
| 4 | 2026-01-13 | 2026-01-13 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 3 | 2025-11-26 | 2025-11-26 | View Filing |
| 8-K | 2025-11-26 | 2025-11-26 | View Filing |
| 3 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-18 | 2025-11-18 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13D/A | 2025-10-28 | 2025-10-28 | View Filing |
| 4 | 2025-10-15 | 2025-10-15 | View Filing |
| 4 | 2025-10-10 | 2025-10-10 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-09-30 | 2025-09-30 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| SC 13D | 2025-09-18 | 2025-09-18 | View Filing |
| SC 13D | 2025-09-18 | 2025-09-18 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-09 | 2025-09-09 | View Filing |
| 4 | 2025-09-08 | 2025-09-08 | View Filing |
| 8-K | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| 3 | 2025-08-06 | 2025-08-06 | View Filing |
| SC 13G | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-11 | 2025-07-11 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| S-3ASR | 2025-03-28 | 2025-03-28 | View Filing |
| 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-01-28 | 2025-01-28 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 424B4 | 2024-12-13 | 2024-12-13 | View Filing |
| EFFECT | 2024-12-13 | 2024-12-13 | View Filing |
| S-1/A | 2024-12-11 | 2024-12-11 | View Filing |
| S-1 | 2024-12-11 | 2024-12-11 | View Filing |
| 4 | 2024-12-06 | 2024-12-06 | View Filing |
| 8-K | 2024-12-05 | 2024-12-05 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-10-08 | 2024-10-08 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-08-30 | 2024-08-30 | View Filing |
| 144 | 2024-08-29 | 2024-08-29 | View Filing |
| 144 | 2024-08-29 | 2024-08-29 | View Filing |
| 144 | 2024-08-29 | 2024-08-29 | View Filing |
| 144 | 2024-08-29 | 2024-08-29 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| SC 13G | 2024-07-22 | 2024-07-22 | View Filing |
| 8-K | 2024-05-24 | 2024-05-24 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Bollinger Bands Strategy | 28.20% | 1.03 | 84 | 0.04 | 0.12 | 35.38 |
| Keltner Channel Strategy | 16.40% | 1.01 | 156 | 0.03 | 0.09 | 23.58 |
| Volume Gap | 14.33% | 1 | 822 | 0.01 | 0.03 | 21.51 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | x |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |